Insider Trading November 19, 2026 08:45 PM

Tempus AI CFO Offloads $446,087 in Stock to Cover Tax Obligations

James William Rogers sells 7,079 shares as mandated by equity incentive plan; stock falls 16.75% over the past week.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
TEM

Tempus AI CFO James William Rogers sold 7,079 Class A shares for $446,087 on November 17, 2026, at prices between $62.33 and $64.02. The sale was a non-discretionary 'sell to cover' transaction tied to tax withholding on vesting restricted stock units. After the sale, Rogers beneficially owns 98,945 shares. Tempus AI's stock has dropped 16.75% over the past week to $59.61, and an analysis suggests the stock appears overvalued. Separately, Tempus AI amended its AstraZeneca agreement for a new five-year, $200 million commitment starting January 1, 2027, with annual payments of at least $32 million. Analyst firms have recently raised price targets and upgraded the stock, citing strong quarterly results and growth in Data and Applications segments.

Tempus AI CFO Offloads $446,087 in Stock to Cover Tax Obligations
TEM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tempus AI CFO James William Rogers sold 7,079 shares for $446,087 in a non-discretionary 'sell to cover' transaction tied to RSU vesting tax obligations.
  • The stock has fallen 16.75% over the past week to $59.61, and an analysis indicates it appears overvalued at current levels.
  • Tempus AI amended its AstraZeneca agreement for a new five-year, $200 million commitment with annual payments of at least $32 million, and several analysts recently raised price targets or upgraded the stock.

Tempus AI, Inc. (NASDAQ: TEM) disclosed that its Chief Financial Officer, James William Rogers, sold 7,079 shares of the company's Class A Common Stock on November 17, 2026. The transaction generated proceeds of $446,087, with the shares changing hands at prices between $62.33 and $64.02. Since the sale, Tempus AI's stock has retreated to $59.61, marking a 16.75% decline over the past week.

The sale was not a discretionary trade by the CFO. Instead, it was a mandatory 'sell to cover' transaction, executed to satisfy statutory tax withholding obligations arising from the vesting of restricted stock units. Tempus AI's equity incentive plans require such sales to cover tax liabilities associated with RSU vesting. Following the transaction, Rogers beneficially owns 98,945 shares of Tempus AI Class A Common Stock.

An analysis of the stock suggests that Tempus AI appears overvalued at current levels. Investors seeking more detailed insights can access a comprehensive Pro Research Report covering TEM and over 1,400 other US equities.

In other recent developments, Tempus AI has amended its agreement with AstraZeneca, establishing a new five-year commitment valued at $200 million. Effective January 1, 2027, the agreement ensures AstraZeneca will pay Tempus AI an annual target of $40 million, with a minimum of $32 million per year throughout the renewal period.

Several analyst firms have also adjusted their outlooks on Tempus AI. H.C. Wainwright raised its price target to $85 while maintaining a Buy rating, based on an increased valuation multiple. BTIG lifted its price target to $100, citing strong quarterly results and improved guidance. Jefferies upgraded Tempus AI from Underperform to Hold, setting a new price target of $70, driven by growth in its Data and Applications segments and strategic collaborations. Needham increased its price target to $89, attributing the move to Tempus AI's impressive third-quarter revenue and adjusted EBITDA that surpassed expectations.

Tempus AI Inc (TEM) closed at $59.61, down $4.01 or 6.30%, on the day. In after-hours trading, the stock was at $58.52, down an additional $1.09 or 1.83%.

Risks

  • The stock's recent 16.75% decline and overvaluation assessment suggest potential for further price weakness, impacting technology and healthcare sectors.
  • The CFO's sale, while non-discretionary, could be perceived negatively by investors, adding selling pressure on the stock.
  • Analyst price targets and ratings may be subject to change based on future performance, introducing uncertainty for investors.

More from Insider Trading

CervoMed CEO John Alam Buys $152,621 in Company Stock Nov 19, 2026 United Therapeutics EVP Mahon Offloads $4.69 Million in Stock Under 10b5-1 Plan Nov 19, 2026 NexPoint Director Offloads $56,750 in Stock as Shares Hover Near 52-Week Low Nov 19, 2026 NexPoint Residential CFO Paul Richards Buys $14,740 in Company Stock Nov 19, 2026 Kinetik Director ISQ Global Fund II Offloads $1.78 Million in Stock Nov 19, 2026